Influenza-A-virus-H1N1-vaccine - Codagenix

Drug Profile

Influenza-A-virus-H1N1-vaccine - Codagenix

Alternative Names: CodaVax; CodaVax-H1N1; H1N1 live-attenuated influenza vaccine - Codagenix

Latest Information Update: 22 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Codagenix
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 06 Mar 2017 Phase-I clinical trials in Influenza virus infections (In volunteers, Prevention) in Australia (Intranasal)
  • 05 Jan 2017 Codagenix plans a phase I/II trial for influenza virus infections in the first quarter of 2017
  • 05 Jan 2017 Codagenix plans a phase I trial for Influenza virus infections (In volunteers) in Australia (ACTRN12617000254392; 9209858)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top